Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab

Diabetes Care. 2005 Feb;28(2):445-7. doi: 10.2337/diacare.28.2.445.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Retinopathy / drug therapy*
  • Female
  • Humans
  • Infliximab
  • Macular Edema / drug therapy*
  • Macular Edema / etiology
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab